US20080119565A1 - Novel compounds from antrodia camphorata - Google Patents

Novel compounds from antrodia camphorata Download PDF

Info

Publication number
US20080119565A1
US20080119565A1 US12/021,584 US2158408A US2008119565A1 US 20080119565 A1 US20080119565 A1 US 20080119565A1 US 2158408 A US2158408 A US 2158408A US 2008119565 A1 US2008119565 A1 US 2008119565A1
Authority
US
United States
Prior art keywords
antroquinonol
compound
cancer
cells
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/021,584
Other versions
US7385088B1 (en
Inventor
Sheng-Yun Liu
Mao-Tien Kuo
Wu-Che Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Golden Biotechnology Corp
Original Assignee
Golden Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corp filed Critical Golden Biotechnology Corp
Assigned to GOLDEN BIOTECHNOLOGY CORPORATION reassignment GOLDEN BIOTECHNOLOGY CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KUO, MAO-TIEN, LIU, SHENG-YUN, WEN, WU-CHE
Publication of US20080119565A1 publication Critical patent/US20080119565A1/en
Application granted granted Critical
Publication of US7385088B1 publication Critical patent/US7385088B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings with unsaturation at least in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C7/00—Purification; Separation; Use of additives
    • C07C7/005—Processes comprising at least two steps in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the present invention relates to novel compounds and use thereof, in particular to Antroquinonol B and Antroquinonol C compounds isolated from Antrodia camphorata extracts and their use in growth inhibition of tumor cells.
  • the compounds from Antrodia camphorata are first reported, which can be applied not only in inhibiting growth of breast cancer, lung cancer, hepatic cancer and prostate cancer, but also in anti-cancer medicinal compositions for the abovementioned cancer cells.
  • Antrodia camphorata is also called Chang-Zhi, Niu Chang-Gu, red camphor mushroom and the like, which is a perennial mushroom belonging to the order Aphyllophorales, the family Polyporaceae. It is an endemic species in Taiwan growing on the inner rotten heart wood wall of Cinnamomum kanehirae Hay. Cinnamoum kanehirai Hay is rarely distributed and being overcut unlawfully, which makes Antrodia camphorata growing inside the tree in the wild became even rare. The price of Antrodia camphorata is very expensive due to the extremely slow growth rate of natural Antrodia camphorata that only grows between June to October.
  • the fruiting bodies of Antrodia camphorata are perennial, sessile, hard and woody, which exhales strong smell of sassafras (camphor aroma).
  • the appearances are various with plate-like, bell-like, hoof-like, or tower-like shapes. They are reddish in color and flat when young, attached to the surface of wood. Then the brims of the front end become little curled tilted and extend to the surroundings. The color turns to be faded red-brown or cream yellow brown, with ostioles all over. This region is of very high medical value.
  • Antrodia camphorata is commonly used as an antidotal, liver protective, anti-cancer drug.
  • Antrodia camphorata like general edible and medicinal mushrooms, is rich in numerous nutrients including triterpenoids, polysaccharides (such as ⁇ -glucosan), adenosine, vitamins (such as vitamin B, nicotinic acid), proteins (immunoglobulins), superoxide dismutase (SOD), trace elements (such as calcium, phosphorus and germanium and so on), nucleic acid, steroids, and stabilizers for blood pressure (such as antodia acid) and the like.
  • These physiologically active ingredients are believed to exhibit effects such as: anti-tumor activities, increasing immuno-modulating activities, anti-allergy, anti-bacteria, anti-high blood pressure, decreasing blood sugar, decreasing cholesterol, and the like.
  • Triterpenoids are the most studied component among the numerous compositions of Antrodia camphorata . Triterpenoids are the summary terms for natural compounds, which contain 30 carbon atoms with the pent acyclic or hex acyclic structures. The bitter taste of Antrodia camphorata is from the component of triterpenoids. Three novel ergostane-type triterpenoids (antcin A-antcin B-antcin C) were isolated by Cherng et al. from the fruiting bodies of Antrodia camphorata (Cherng, I. H., and Chiang, H. C. 1995. Three new triterpenoids from Antrodia cinnamomea . J. Nat. Prod. 58:365-371).
  • Antrodia camphorata extracts were reported to have the anti-tumor effects from previous experiments (such as the reference mentioned above: Chen & Yang, 1995), further experiments are needed to identify the effective composition for tumor inhibition. The application in cancer therapy will be of great beneficial effects if the real effective compositions are found.
  • the compound of formula (1) was isolated and purified in the present invention, where X can be hydroxyl (—OH) or methoxy (—OCH 3 ).
  • Compounds Antroquinonol B and Antroquinonol C are purified from aqueous extraction or organic solvent extraction of Antrodia camphorata .
  • the organic solvents used include, but not limited to, alcohols such as methanol, ethanol or propanol, esters such as ethyl acetate, alkanes such as hexane, or halogenated alkanes such as chloromethane, chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
  • the abovementioned compounds in the present invention can be applied in inhibiting tumor cell growth, which can further be used as a medicinal composition to treat cancer and to enhance the therapeutic effects.
  • the compounds of the present invention can be applied in inhibiting a range of cancer cells, including breast cancer, lung cancer, hepatic cancer and prostate cancer, leading to a marked slowering of the growth of cancer cells, and further inhibiting proliferation of cancer cells and decreasing the risk of malignancy. Therefore they can be used for the treatment of breast cancer, lung cancer, hepatic cancer, prostate cancer and more.
  • the compounds of formula (2) and/or formula (3) in the present invention can be incorporated into medicinal compositions for treating breast cancer, lung cancer, hepatic cancer, and prostate cancer to inhibit the growth of tumor cells.
  • the medicinal compositions include not only the effective amounts of Antroquinonol B and Antroquinonol C, but also the pharmaceutically accepted carries.
  • the carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners.
  • compositions of the present invention can be manufactured through mixing the compounds of Antroquinonol B and Antroquinonol C with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated, but are not limited to, as a powder, tablet, capsule, pellets, granules or other liquid formulation.
  • the mycelia, fruiting bodies or mixture of both from Antrodia camphorata are first extracted with water or organic solvents to obtain the aqueous extract or organic solvent extract of Antrodia camphorata using the methods well known in the arts.
  • the organic solvents include, but not limited to, alcohols such as methanol; ethanol or propanol; esters such as Ethyl acetate; alkanes such as hexane; or halogenated alkanes such as chloromethane, and chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
  • the aqueous or organic solvent extracts of Antrodia camphorate were subjected to high-performance liquid chromatography (HPLC) for isolation and purification. Each fraction was recovered and applied to anti-tumor assay. The potent fractions with anti-tumor ability were analyzed for the composition and further assayed against different cancer cells.
  • HPLC high-performance liquid chromatography
  • Antroquinonol B and Antroquinonol C were demonstrated with anti-cancer effects using 3-(4,5-dimethylthiazol-2-yl)-2, S-diphenyl tetrazolium bromide (MTT) assay according to the anti-tumor drugs screening model of National Cancer Institute (NCI) on cell survival rates using cell lines of breast cancer, lung cancer, hepatic cancer, prostate cancer.
  • NCI National Cancer Institute
  • Antroquinonol B and Antroquinonol C decreased survival rates of breast cancer cell lines (MCF-7 and MDA-MB-231), lung cancer cell lines (A-549), hepatocellular carcinoma cell lines (Hep 3B and Hep G2) and prostate cancer cell lines (LNCaP and DU-145), at the same time showed relatively low half-maximal inhibitory concentration (IC 50 ) values. Therefore Antroquinonol B and Antroquinonol C can be used in inhibiting cancer cell growth of breast cancer, lung cancer, hepatic cancer, and prostate cancer, which can further be applied in cancer treatment of breast cancer, lung cancer, hepatic cancer, prostate cancer and the like. The details of the examples are described as follows:
  • the filtrate of Antrodia camphorata was subjected to High Performance Liquid chromatography (HPLC) analysis.
  • HPLC High Performance Liquid chromatography
  • the separation was performed on a RP18 column, the mobile phase consisted of methanol (A) and 0.1-0.5% acetic acid (B), with the gradient conditions of 0-10 min in 95% ⁇ 20% B, 10-20 min in 20% ⁇ 10% B, 20-35 min in 10% ⁇ 90% B, 35-40 min in 10% ⁇ 95% B, at the flow rate of 1 ml/min.
  • the column effluent was monitored with a UV-visible detector.
  • Antroquinonol B and Antroquinonol C were compared in the chemical compound database. No compound with similar structure was discovered. Therefore, these compounds are regarded as novel compounds since they have never been reported previously.
  • the NCI anti-cancer drug screen model was adopted to test the anti-cancer effect of the isolated compounds from example 1 in the present invention.
  • the isolated Antroquinonol B and Antroquinonol C from example 1 were added into the culture media of human breast-cancer cells, MCF-7 or MDA-MB-231, to test for tumor cell survival.
  • This survival assay was carried out with the widely known MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide) assay.
  • MCF-7 cell line is originated from primary breast cancer cells (early stage), sensitive to estrogen and therefore is estrogen-dependent, while MDA-MB-231 is insensitive to estrogen and therefore is estrogen-independent, which is a difficult tumor with a low survival rate.
  • MTT assay is commonly used to determine cell proliferation, percent of viable cells, and cytotoxicity.
  • 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) is a yellow dye, which can be absorbed by the living cells and be reduced to purplish blue formazan crystals by succinate tetrazolium reductase in mitochondria. Formazan formation can therefore be used to assess and determine the survival rate of cells.
  • the human breast-cancer cells MCF-7 (purchased from the Bioresources Collection and Research Center (BCRC) with the accession number of BCRC60436) and MDA-MB-231 (purchased from National Health Research Institutes (NHRI) with the accession number of CCRC 60425) were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1 ⁇ trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate.
  • BCRC Bioresources Collection and Research Center
  • NHRI National Health Research Institutes
  • Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 ⁇ g/ml, respectively.
  • the cells were incubated at 37° C. in a 5% CO 2 incubator for 48 hours.
  • MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 100 ⁇ l of lysis buffer to stop the reaction.
  • the plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates.
  • the half maximal inhibitory concentration (IC 50 ) values were also calculated and listed in Table 1.
  • Antroquinonol B and Antroquinonol C are capable of decreasing the survival rate of estrogen-dependent breast cancer cell MCF-7 from the result of Table 1.
  • the IC 50 value of Antroquinonol B toward MCF-7 was dropped to 1.94 ⁇ g/ml, which was 82.56% lower than that of crude extracts from A. camphorata (11.13 ⁇ g/ml).
  • the IC 50 value of Antroquinonol C toward MCF-7 was dropped to 1.17 ⁇ g/ml, which was 89.49% lower than that of crude extracts from A. camphorata (11.13 ⁇ g/ml). Therefore Antroquinonol B and Antroquinonol C from Antrodia camphorata can be applied to inhibit the growth of estrogen-dependent breast cancer cells MCF-7.
  • Antroquinonol B and Antroquinonol C are capable of decreasing the survival rate of estrogen-independent breast cancer cell MDA-MB-231.
  • the IC 50 values of Antroquinonol B and Antroquinonol C toward MDA-MB-231 were 8.72 ⁇ g/ml and 21.9 ⁇ g/ml respectively, which were 66.21% and 15.15% lower than that of crude extracts from A. camphorata (25.81 ⁇ g/ml).
  • Antroquinonol B and Antroquinonol C needed for the half maximal inhibitory concentration of MDA-MB-231 were all lowered than the crude extracts in the control group, and a better inhibitory effect was found in Antroquinonol B. Therefore Antroquinonol B and Antroquinonol C from Antrodia camphorata can be applied to inhibit the growth of estrogen-independent breast cancer cells MDA-MB-231.
  • the NCI anti-cancer drug screen model was also employed to test the anti-lung cancer effect of the Antroquinonol B and Antroquinonol C in the present invention.
  • the Antroquinonols isolated from example 1 were added into the culture media of human lung cancer cell A549 with the abovementioned MTT assay to analyze lung cancer cell survival rates.
  • Human lung cancer cell A549 was obtained from the Bioresources Collection and Research Center (BCRC) of the Food Industry Research and Development Institute with an accession number of BCRC 60074.
  • A549 cells were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1 ⁇ trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate.
  • Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 ⁇ g/ml, respectively.
  • the cells were incubated at 37° C. in a 5% CO 2 incubator for 48 hours.
  • MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 100 ⁇ l of lysis buffer to stop the reaction.
  • the plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates.
  • IC 50 values The half-maximal inhibitory concentration (IC 50 values) were also calculated and listed in Table 2. TABLE 2 Results of ex vivo survival assay for inhibition of lung cancer cells IC 50 ( ⁇ g/ml) Samples A549 Control Crude extracts of 13.21 group A. camphorata Experimental Antroquinonol B 11.9 group Antroquinonol C 8.21
  • Antroquinonol B and Antroquinonol C can effectively decrease the survival rates of human lung cancer cell line A549.
  • the IC 50 value of Antroquinonol B and Antroquinonol C toward A549 were 11.9 ⁇ g/ml and 8.21 ⁇ g/ml respectively, which were 9.92% and 37.85% lower than that of crude extracts from A. camphorata (13.21 ⁇ g/ml). Both Antroquinonol B and Antroquinonol C had reduced IC 50 values than the control group, and a better inhibitory effect was found in Antroquinonol B. Therefore Antroquinonol B and Antroquinonol C from A. camphorata can be applied to inhibit the growth of lung cancer cells A549.
  • the NCI anti-cancer drug screen model was employed to test the anti-cancer effect of the Antroquinonol B and Antroquinono C in the present invention.
  • the Antroquinonos isolated from example 1 were added into the culture media of human hepatic-cancer cells, Hep 3B or Hep G2, for tumor cell survival assay.
  • Hepatic-cancer cells Hep 3B (BCRC 60434) and Hep G2 (BCRC 60025) were obtained from the Bioresources Collection and Research Center (BCRC) of the Food Industry Research and Development Institute.
  • the human hepatic-cancer cells Hep 3B and Hep G2 were cultivated in media containing fetal calf serum for 24 hours.
  • the proliferated cells were washed once with PBS, then treated with 1 ⁇ trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking.
  • the cells were placed in a 96-well plate.
  • Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 ⁇ g/ml, respectively.
  • the cells were incubated at 37° C. in a 5% CO 2 incubator for 48 hours.
  • MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 1001 of lysis buffer to stop the reaction.
  • the plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates.
  • Antroquinonol B and Antroquinonol C can effectively decrease the survival rates of human hepatic cancer cell line Hep 3B and Hep G2.
  • the IC 50 value of Antroquinonol B toward Hep 3B were 1.21 ⁇ g/ml, which was 76.27% lower than that of crude extracts from A. camphorata (5.10 g/ml).
  • the IC 50 value of Antroquinonol C toward Hep 3B were 1.32 ⁇ g/ml, which was 74.12% lower than that of crude extracts from A. camphorata . Both compounds showed remarkedly decrease IC 50 values than the control group in Hep3B cells.
  • Antroquinonol B and Antroquinonol C toward Hep G2 were 3.32 ⁇ g/ml and 5.12 ⁇ g/ml respectively, which were 82.18% and 72.52% lower than that of crude extracts from A. camphorata (18.63 ⁇ g/ml). Both compounds showed remarkedly decrease IC 50 values than the control group in HepG2 cells. Therefore Antroquinonol B and Antroquinonol C from A. camphorata can be applied to inhibit the growth of hepatic cancer cells.
  • hepatic cancer cells treated with Antroquinonol B showed lower IC 50 values than cells treated with Antroquinonol C, that is, lower concentration of Antroquinonol B was needed in inhibiting growth the hepatic cancer cells Hep 3B and Hep G2.
  • Antroquinonol B has better inhibiting effects than Antroquinonol C toward the growth of hepatic cancer cells.
  • the NCI anti-cancer drug screen model was also employed to test the anti-cancer effect of the Antroquinonols in the present invention.
  • Antroquinonol B and Antroquinonol C isolated from example 2 were added into the culture media of human prostate cancer cells, LNCaP or DU-145, and prostate cancer cell survival rates were analyzed with the abovementioned MTT assay.
  • LNCaP is originated from epithelial cells of prostate gland, which depends on androgen in the early stage and thus is androgen-dependent cancer cell.
  • DU-145 is recurrent type prostate cancer cell, which does not rely on androgen for growth and therefore is androgen-independent. This recurrent type prostate cancer has no effective treatment so far.
  • Both LNCaP and DU-145 were ordered from NHRI with accession numbers of CCRC 60088 and CCRC 60348 respectively.
  • the human prostate-cancer cells LNCaP and DU-145, were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1 ⁇ trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate.
  • Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 ⁇ g/ml, respectively.
  • the cells were incubated at 37° C. in a 5% CO 2 incubator for 48 hours.
  • MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 1001 of lysis buffer to stop the reaction.
  • the plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates.
  • the IC 50 values of Antroquinonol B and Antroquinonol C toward DU-145 were 10.12 ⁇ g/ml and 12.21 ⁇ g/ml respectively, which were 75.55% and 70.5% lower than the IC 50 value of the control group (41.39 ⁇ g/ml). Therefore the half maximal inhibitory concentrations of these two Antroquinonols from A. camphorata were remarkedly reduced toward prostate cancer cells LNCaP and DU-145 in comparison to the crude extracts in the control group.
  • LNCaP prostate cancer cells treated with Antroquinonol B showed a much lower IC 50 values than Antroquinonol C treated cells, that is, a better inhibitory effect was found in Antroquinonol B for inhibiting prostate cancer cells.
  • Antroquinonol B and Antroquinonol C can effectively inhibit the growth of LNCaP and DU-145 prostate cancer cells with two different characteristics. Therefore Antroquinonol B and Antroquinonol C can be applied in inhibiting not only the growth of androgen-dependent prostate cancer cells LNCaP, but also androgen-independent prostate cancer cells DU-145. This is beneficial to the therapy of prostate cancer and recurrent prostate cancer.
  • Antroquinonol B and Antroquinonol C purified from extracts of A. camphorata can effectively inhibit the growth of breast cancer, lung cancer, hepatic cancer and prostate cancer. These compounds can be incorporated into medicinal compositions for treating the abovementioned cancer cells.
  • the medicinal compositions include not only the compounds of Antroquinonol B and Antroquinonol C, but also the pharmaceutically accepted carries.
  • the carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners.
  • the inventive composition can be manufactured through mixing the compounds of Antroquinonol B or Antroquinonol C with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated, but are not limited to, as a powder, tablet, capsule, pellets, granules or other liquid formulation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Water Supply & Treatment (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a novel compound and use thereof, in particular to Antroquinonol B and Antroquinonol C isolated from Antrodia camphorata extracts which can effectively inhibit the growth of cancer cells. The compounds from Antrodia camphorata are first reported, which can be applied not only in inhibiting growth of breast cancer, lung cancer, hepatic cancer and prostate cancer, but also in anti-cancer medicinal compositions for the abovementioned cancer cells.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to novel compounds and use thereof, in particular to Antroquinonol B and Antroquinonol C compounds isolated from Antrodia camphorata extracts and their use in growth inhibition of tumor cells. The compounds from Antrodia camphorata are first reported, which can be applied not only in inhibiting growth of breast cancer, lung cancer, hepatic cancer and prostate cancer, but also in anti-cancer medicinal compositions for the abovementioned cancer cells.
  • 2. The Prior Arts
  • Antrodia camphorata is also called Chang-Zhi, Niu Chang-Gu, red camphor mushroom and the like, which is a perennial mushroom belonging to the order Aphyllophorales, the family Polyporaceae. It is an endemic species in Taiwan growing on the inner rotten heart wood wall of Cinnamomum kanehirae Hay. Cinnamoum kanehirai Hay is rarely distributed and being overcut unlawfully, which makes Antrodia camphorata growing inside the tree in the wild became even rare. The price of Antrodia camphorata is very expensive due to the extremely slow growth rate of natural Antrodia camphorata that only grows between June to October.
  • The fruiting bodies of Antrodia camphorata are perennial, sessile, hard and woody, which exhales strong smell of sassafras (camphor aroma). The appearances are various with plate-like, bell-like, hoof-like, or tower-like shapes. They are reddish in color and flat when young, attached to the surface of wood. Then the brims of the front end become little curled tilted and extend to the surroundings. The color turns to be faded red-brown or cream yellow brown, with ostioles all over. This region is of very high medical value.
  • In traditional Taiwanese medicine, Antrodia camphorata is commonly used as an antidotal, liver protective, anti-cancer drug. Antrodia camphorata, like general edible and medicinal mushrooms, is rich in numerous nutrients including triterpenoids, polysaccharides (such as β-glucosan), adenosine, vitamins (such as vitamin B, nicotinic acid), proteins (immunoglobulins), superoxide dismutase (SOD), trace elements (such as calcium, phosphorus and germanium and so on), nucleic acid, steroids, and stabilizers for blood pressure (such as antodia acid) and the like. These physiologically active ingredients are believed to exhibit effects such as: anti-tumor activities, increasing immuno-modulating activities, anti-allergy, anti-bacteria, anti-high blood pressure, decreasing blood sugar, decreasing cholesterol, and the like.
  • Triterpenoids are the most studied component among the numerous compositions of Antrodia camphorata. Triterpenoids are the summary terms for natural compounds, which contain 30 carbon atoms with the pent acyclic or hex acyclic structures. The bitter taste of Antrodia camphorata is from the component of triterpenoids. Three novel ergostane-type triterpenoids (antcin A-antcin B-antcin C) were isolated by Cherng et al. from the fruiting bodies of Antrodia camphorata (Cherng, I. H., and Chiang, H. C. 1995. Three new triterpenoids from Antrodia cinnamomea. J. Nat. Prod. 58:365-371). Three new compounds zhankuic acid A, zhankuic acid B and zhankuic acid were extracted from the fruiting bodies of Antrodia camphorata with ethanol by Chen et al. (Chen, C. H., and Yang, S. W. 1995. New steroid acids from Antrodia cinnamomea, —a fungus parasitic on Cinnamomum micranthum. J. Nat. Prod. 58:1655-1661). In addition, Cherng et al. also found three other new triterpenoids from the fruiting bodies of Antrodia camphorata, which are sesquiterpene lactone and 2 biphenyl derived compounds, 4,7-dimethoxy-5-methyl-1,3-benzodioxole and 2,2′,5,5′-teramethoxy-3,4,3′,4′-bi-methylenedioxy-6,6′-dimethylbiphenyl (Chiang, H. C., Wu, D. P., Cherng, I. W., and Ueng, C. H. 1995. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry. 39:613-616). In 1996, four novel ergostane-type triterpenoids (antcins E and F and methyl antcinates G and H) were isolated by Cherng et al. with the same analytic methods (Cherng, I. H., Wu, D. P., and Chiang, H. C. 1996. Triteroenoids from Antrodia cinnamomea. Phytochemistry. 41:263-267). And two ergostane related steroids, zhankuic acids D and E together with three lanosta related triterpenes, 15 alpha-acetyl-dehydrosulphurenic acid, dehydroeburicoic acid, dehydrosulphurenic acid were isolated by Yang et al. (Yang, S. W., Shen, Y. C., and Chen, C. H. 1996. Steroids and triterpenoids of Antrodia cinnamomea—a fungus parasitic on Cinnamomum micranthum. Phytochemistry. 41: 1389-1392).
  • Although Antrodia camphorata extracts were reported to have the anti-tumor effects from previous experiments (such as the reference mentioned above: Chen & Yang, 1995), further experiments are needed to identify the effective composition for tumor inhibition. The application in cancer therapy will be of great beneficial effects if the real effective compositions are found.
    • SUMMARY OF THE INVENTION
  • In order to identify the compounds containing anti-tumor effects from the extracts of Antrodia camphorata, the compound of formula (1) was isolated and purified in the present invention, where X can be hydroxyl (—OH) or methoxy (—OCH3).
    Figure US20080119565A1-20080522-C00001
  • When X is hydroxyl, the structure is as shown in formula (2). The chemical name is Antroquinonol B, with molecular formula of C24H38O5 and molecular weight of 406.
    Figure US20080119565A1-20080522-C00002
  • When X is methoxy, the structure is as shown in formula (3). The chemical name is Antroquinonol C, with molecular formula of C25H40O5 and molecular weight of 420.
    Figure US20080119565A1-20080522-C00003
  • Compounds Antroquinonol B and Antroquinonol C are purified from aqueous extraction or organic solvent extraction of Antrodia camphorata. The organic solvents used include, but not limited to, alcohols such as methanol, ethanol or propanol, esters such as ethyl acetate, alkanes such as hexane, or halogenated alkanes such as chloromethane, chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
  • The abovementioned compounds in the present invention can be applied in inhibiting tumor cell growth, which can further be used as a medicinal composition to treat cancer and to enhance the therapeutic effects. The compounds of the present invention can be applied in inhibiting a range of cancer cells, including breast cancer, lung cancer, hepatic cancer and prostate cancer, leading to a marked slowering of the growth of cancer cells, and further inhibiting proliferation of cancer cells and decreasing the risk of malignancy. Therefore they can be used for the treatment of breast cancer, lung cancer, hepatic cancer, prostate cancer and more.
  • On the other hand, the compounds of formula (2) and/or formula (3) in the present invention can be incorporated into medicinal compositions for treating breast cancer, lung cancer, hepatic cancer, and prostate cancer to inhibit the growth of tumor cells. The medicinal compositions include not only the effective amounts of Antroquinonol B and Antroquinonol C, but also the pharmaceutically accepted carries. The carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners. The compositions of the present invention can be manufactured through mixing the compounds of Antroquinonol B and Antroquinonol C with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated, but are not limited to, as a powder, tablet, capsule, pellets, granules or other liquid formulation.
  • The present invention is further explained in the following embodiment illustration and examples. Those examples below should not, however, be considered to limit the scope of the invention, it is contemplated that modifications will readily occur to those skilled in the art, which modifications will be within the spirit of the invention and the scope of the appended claims.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • The mycelia, fruiting bodies or mixture of both from Antrodia camphorata are first extracted with water or organic solvents to obtain the aqueous extract or organic solvent extract of Antrodia camphorata using the methods well known in the arts. The organic solvents include, but not limited to, alcohols such as methanol; ethanol or propanol; esters such as Ethyl acetate; alkanes such as hexane; or halogenated alkanes such as chloromethane, and chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
  • The aqueous or organic solvent extracts of Antrodia camphorate were subjected to high-performance liquid chromatography (HPLC) for isolation and purification. Each fraction was recovered and applied to anti-tumor assay. The potent fractions with anti-tumor ability were analyzed for the composition and further assayed against different cancer cells. The above approach then led to the identification of compounds of Antroquinonol B and Antroquinonol C in inhibiting the growth of breast cancer, lung cancer, hepatic cancer, prostate cancer and more. These compounds from Antrodia camphorata are regarded as novel compounds since they have never been reported in any literatures.
  • The compounds of Antroquinonol B and Antroquinonol C were demonstrated with anti-cancer effects using 3-(4,5-dimethylthiazol-2-yl)-2, S-diphenyl tetrazolium bromide (MTT) assay according to the anti-tumor drugs screening model of National Cancer Institute (NCI) on cell survival rates using cell lines of breast cancer, lung cancer, hepatic cancer, prostate cancer. The above assays had proved that Antroquinonol B and Antroquinonol C decreased survival rates of breast cancer cell lines (MCF-7 and MDA-MB-231), lung cancer cell lines (A-549), hepatocellular carcinoma cell lines (Hep 3B and Hep G2) and prostate cancer cell lines (LNCaP and DU-145), at the same time showed relatively low half-maximal inhibitory concentration (IC50) values. Therefore Antroquinonol B and Antroquinonol C can be used in inhibiting cancer cell growth of breast cancer, lung cancer, hepatic cancer, and prostate cancer, which can further be applied in cancer treatment of breast cancer, lung cancer, hepatic cancer, prostate cancer and the like. The details of the examples are described as follows:
    • EXAMPLE 1 Isolation of Antroquinonol B and Antroquinonol C
  • One hundred grams of mycelia, fruiting bodies or mixture of both from Antrodia camphorata were placed into a flask. A proper amount of water and alcohol (70-100% alcohol solution) was added into the flask and were stirred at 20-25° C. for at least 1 hour. The solution was filtered through a filter and a 0.45 μm membrane and the filtrate was collected as the extract.
  • The filtrate of Antrodia camphorata was subjected to High Performance Liquid chromatography (HPLC) analysis. The separation was performed on a RP18 column, the mobile phase consisted of methanol (A) and 0.1-0.5% acetic acid (B), with the gradient conditions of 0-10 min in 95%˜20% B, 10-20 min in 20%˜10% B, 20-35 min in 10%˜90% B, 35-40 min in 10%˜95% B, at the flow rate of 1 ml/min. The column effluent was monitored with a UV-visible detector.
  • The fractions collected at 21.2-21.4 min were collected and concentrated to yield Antroquinonol B, a product of pale yellow powder. The analysis of this product showed the molecular formula of C24H38O5, molecular weight of 406. Investigation of NMR spectra showed that 1H-NMR (CDCl3) δ (ppm)=1.21, 1.36, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.68, 4.05, 5.71, and 5.56; 13C-NMR (CDCl3) δ (ppm)=12.31, 16.1, 16.12, 17.67, 25.67, 26.44, 26.74, 27.00, 39.71, 39.81, 4.027, 43.34, 59.22, 60.59, 71.8, 120.97, 123.84, 124.30, 131.32, 134.61, 135.92, 138.05, 160.45, and 197.11.
  • The fractions collected at 23.7-24 min were collected and concentrated to yield Antroquinonol C, a product of pale yellow powder. The analysis of this product showed the molecular formula of C25H40O5, molecular weight of 420. Investigation of NMR spectra showed that 1H-NMR (CDCl3) δ (ppm)=1.21, 1.36, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.24, 3.68, 4.05, 5.12, 5.50, and 5.61; 13C-NMR (CDCl3) δ (ppm)=12.31, 16.1, 16.12, 17.67, 24.44, 26.44, 26.74, 27.00, 37.81, 39.81, 4.027, 43.34, 49.00, 59.22, 60.59, 120.97, 123.84, 124.30, 135.92, 138.05, 160.45, and 197.12.
  • The structures of Antroquinonol B and Antroquinonol C were compared in the chemical compound database. No compound with similar structure was discovered. Therefore, these compounds are regarded as novel compounds since they have never been reported previously.
    • EXAMPLE 2 Ex Vivo Survival Assay for Anti-Breast Cancer Effects
  • The NCI anti-cancer drug screen model was adopted to test the anti-cancer effect of the isolated compounds from example 1 in the present invention. The isolated Antroquinonol B and Antroquinonol C from example 1 were added into the culture media of human breast-cancer cells, MCF-7 or MDA-MB-231, to test for tumor cell survival. This survival assay was carried out with the widely known MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide) assay. MCF-7 cell line is originated from primary breast cancer cells (early stage), sensitive to estrogen and therefore is estrogen-dependent, while MDA-MB-231 is insensitive to estrogen and therefore is estrogen-independent, which is a difficult tumor with a low survival rate.
  • MTT assay is commonly used to determine cell proliferation, percent of viable cells, and cytotoxicity. 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) is a yellow dye, which can be absorbed by the living cells and be reduced to purplish blue formazan crystals by succinate tetrazolium reductase in mitochondria. Formazan formation can therefore be used to assess and determine the survival rate of cells.
  • The human breast-cancer cells, MCF-7 (purchased from the Bioresources Collection and Research Center (BCRC) with the accession number of BCRC60436) and MDA-MB-231 (purchased from National Health Research Institutes (NHRI) with the accession number of CCRC 60425) were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1× trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate. Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 μg/ml, respectively. The cells were incubated at 37° C. in a 5% CO2 incubator for 48 hours. MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 100 μl of lysis buffer to stop the reaction. The plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates. The half maximal inhibitory concentration (IC50) values were also calculated and listed in Table 1.
    TABLE 1
    Results of ex vivo survival assay for
    inhibition of breast cancer cells
    IC50(μg/ml)
    Samples MCF-7 MDA-MB-231
    Control Crude extracts of 11.13 25.81
    group A. camphorata
    Experiment Antroquinonol B 1.94 8.72
    group Antroquinonol C 1.17 21.9
  • Antroquinonol B and Antroquinonol C are capable of decreasing the survival rate of estrogen-dependent breast cancer cell MCF-7 from the result of Table 1. The IC50 value of Antroquinonol B toward MCF-7 was dropped to 1.94 μg/ml, which was 82.56% lower than that of crude extracts from A. camphorata (11.13 μg/ml). And the IC50 value of Antroquinonol C toward MCF-7 was dropped to 1.17 μg/ml, which was 89.49% lower than that of crude extracts from A. camphorata (11.13 μg/ml). Therefore Antroquinonol B and Antroquinonol C from Antrodia camphorata can be applied to inhibit the growth of estrogen-dependent breast cancer cells MCF-7.
  • On the other hand, Antroquinonol B and Antroquinonol C are capable of decreasing the survival rate of estrogen-independent breast cancer cell MDA-MB-231. The IC50 values of Antroquinonol B and Antroquinonol C toward MDA-MB-231 were 8.72 μg/ml and 21.9 μg/ml respectively, which were 66.21% and 15.15% lower than that of crude extracts from A. camphorata (25.81 μg/ml). The concentration of Antroquinonol B and Antroquinonol C needed for the half maximal inhibitory concentration of MDA-MB-231 were all lowered than the crude extracts in the control group, and a better inhibitory effect was found in Antroquinonol B. Therefore Antroquinonol B and Antroquinonol C from Antrodia camphorata can be applied to inhibit the growth of estrogen-independent breast cancer cells MDA-MB-231.
    • EXAMPLE 3 Ex Vivo Survival Assay for Anti-Lung Cancer Effects
  • The NCI anti-cancer drug screen model was also employed to test the anti-lung cancer effect of the Antroquinonol B and Antroquinonol C in the present invention. The Antroquinonols isolated from example 1 were added into the culture media of human lung cancer cell A549 with the abovementioned MTT assay to analyze lung cancer cell survival rates.
  • Human lung cancer cell A549 was obtained from the Bioresources Collection and Research Center (BCRC) of the Food Industry Research and Development Institute with an accession number of BCRC 60074. A549 cells were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1× trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate. Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 μg/ml, respectively. The cells were incubated at 37° C. in a 5% CO2 incubator for 48 hours. MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 100 μl of lysis buffer to stop the reaction. The plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates. The half-maximal inhibitory concentration (IC50 values) were also calculated and listed in Table 2.
    TABLE 2
    Results of ex vivo survival assay for
    inhibition of lung cancer cells
    IC50 (μg/ml)
    Samples A549
    Control Crude extracts of 13.21
    group A. camphorata
    Experimental Antroquinonol B 11.9
    group Antroquinonol C 8.21
  • From the result of table 2, Antroquinonol B and Antroquinonol C can effectively decrease the survival rates of human lung cancer cell line A549. The IC50 value of Antroquinonol B and Antroquinonol C toward A549 were 11.9 μg/ml and 8.21 μg/ml respectively, which were 9.92% and 37.85% lower than that of crude extracts from A. camphorata (13.21 μg/ml). Both Antroquinonol B and Antroquinonol C had reduced IC50 values than the control group, and a better inhibitory effect was found in Antroquinonol B. Therefore Antroquinonol B and Antroquinonol C from A. camphorata can be applied to inhibit the growth of lung cancer cells A549.
    • EXAMPLE 4 Ex Vivo Survival Assay for Anti-Hepatic Cancer Effects
  • The NCI anti-cancer drug screen model was employed to test the anti-cancer effect of the Antroquinonol B and Antroquinono C in the present invention. The Antroquinonos isolated from example 1 were added into the culture media of human hepatic-cancer cells, Hep 3B or Hep G2, for tumor cell survival assay. Hepatic-cancer cells Hep 3B (BCRC 60434) and Hep G2 (BCRC 60025), were obtained from the Bioresources Collection and Research Center (BCRC) of the Food Industry Research and Development Institute.
  • The human hepatic-cancer cells, Hep 3B and Hep G2, were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1× trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate. Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 μg/ml, respectively. The cells were incubated at 37° C. in a 5% CO2 incubator for 48 hours. MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 1001 of lysis buffer to stop the reaction. The plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates. The half-maximal inhibitory concentration (IC50) values were also calculated and listed in Table 3.
    TABLE 3
    Results of ex vivo survival assay for
    inhibition of hepatic cancer cells
    IC50 (μg/ml)
    Samples Hep3B HepG2
    Control Crude extracts of 5.10 18.63
    group A. camphorata
    Experimental Antroquinonol B 1.21 3.32
    group Antroquinonol C 1.32 5.12
  • From the result of table 3, Antroquinonol B and Antroquinonol C can effectively decrease the survival rates of human hepatic cancer cell line Hep 3B and Hep G2. The IC50 value of Antroquinonol B toward Hep 3B were 1.21 μg/ml, which was 76.27% lower than that of crude extracts from A. camphorata (5.10 g/ml). The IC50 value of Antroquinonol C toward Hep 3B were 1.32 μg/ml, which was 74.12% lower than that of crude extracts from A. camphorata. Both compounds showed remarkedly decrease IC50 values than the control group in Hep3B cells. The IC50 values of Antroquinonol B and Antroquinonol C toward Hep G2 were 3.32 μg/ml and 5.12 μg/ml respectively, which were 82.18% and 72.52% lower than that of crude extracts from A. camphorata (18.63 μg/ml). Both compounds showed remarkedly decrease IC50 values than the control group in HepG2 cells. Therefore Antroquinonol B and Antroquinonol C from A. camphorata can be applied to inhibit the growth of hepatic cancer cells.
  • In addition, hepatic cancer cells treated with Antroquinonol B showed lower IC50 values than cells treated with Antroquinonol C, that is, lower concentration of Antroquinonol B was needed in inhibiting growth the hepatic cancer cells Hep 3B and Hep G2. Antroquinonol B has better inhibiting effects than Antroquinonol C toward the growth of hepatic cancer cells.
    • EXAMPLE 5 Ex Vivo Survival Assay for Anti-Prostate Cancer Effects
  • The NCI anti-cancer drug screen model was also employed to test the anti-cancer effect of the Antroquinonols in the present invention. Antroquinonol B and Antroquinonol C isolated from example 2 were added into the culture media of human prostate cancer cells, LNCaP or DU-145, and prostate cancer cell survival rates were analyzed with the abovementioned MTT assay. LNCaP is originated from epithelial cells of prostate gland, which depends on androgen in the early stage and thus is androgen-dependent cancer cell. DU-145 is recurrent type prostate cancer cell, which does not rely on androgen for growth and therefore is androgen-independent. This recurrent type prostate cancer has no effective treatment so far. Both LNCaP and DU-145 were ordered from NHRI with accession numbers of CCRC 60088 and CCRC 60348 respectively.
  • The human prostate-cancer cells, LNCaP and DU-145, were cultivated in media containing fetal calf serum for 24 hours. The proliferated cells were washed once with PBS, then treated with 1× trypsin-EDTA and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 10 ml of fresh culture medium by gently shaking. The cells were placed in a 96-well plate. Total ethanol extracts of Antrodia camphorata without purification (the control group), Antroquinonol B or Antroquinonol C (the experimental group) were added into each of the 96 wells at the following concentrations: 30, 10, 3, 1, 0.3, 0.1 and 0.03 μg/ml, respectively. The cells were incubated at 37° C. in a 5% CO2 incubator for 48 hours. MTT was added in a concentration of 2.5 mg/ml into each well in dark and incubated for 4 hours, followed by the addition of 1001 of lysis buffer to stop the reaction. The plates were read on an ELISA reader at wavelength of 570 nm to determine the survival rates. The half-maximal inhibitory concentration (IC50) values were also calculated and listed in Table 4.
    TABLE 4
    Results of ex vivo survival assay for
    inhibition of prostate cancer cells
    IC50 (μg/ml)
    Samples LNCaP DU-145
    Control Crude extracts of 11.49 41.39
    group A. camphorata
    Experimental Antroquinonol A 5.67 10.12
    group Antroquinonol J 8.72 12.21
  • From the result of table 4, the cell survival rates of LNCaP and DU-145 were effectively reduced through the activities of Antroquinonol B or Antroquinonol C. The IC50 values of Antroquinonol B and Antroquinonol C toward LNCaP were 5.67 μg/ml and 8.72 μg/ml respectively, which were 50.65% and 24.11% lower than the IC50 value of the control group (11.49 μg/ml). The IC50 values of Antroquinonol B and Antroquinonol C toward DU-145 were 10.12 μg/ml and 12.21 μg/ml respectively, which were 75.55% and 70.5% lower than the IC50 value of the control group (41.39 μg/ml). Therefore the half maximal inhibitory concentrations of these two Antroquinonols from A. camphorata were remarkedly reduced toward prostate cancer cells LNCaP and DU-145 in comparison to the crude extracts in the control group. In addition, LNCaP prostate cancer cells treated with Antroquinonol B showed a much lower IC50 values than Antroquinonol C treated cells, that is, a better inhibitory effect was found in Antroquinonol B for inhibiting prostate cancer cells.
  • On the other hand, both Antroquinonol B and Antroquinonol C can effectively inhibit the growth of LNCaP and DU-145 prostate cancer cells with two different characteristics. Therefore Antroquinonol B and Antroquinonol C can be applied in inhibiting not only the growth of androgen-dependent prostate cancer cells LNCaP, but also androgen-independent prostate cancer cells DU-145. This is beneficial to the therapy of prostate cancer and recurrent prostate cancer.
  • In summary, Antroquinonol B and Antroquinonol C purified from extracts of A. camphorata can effectively inhibit the growth of breast cancer, lung cancer, hepatic cancer and prostate cancer. These compounds can be incorporated into medicinal compositions for treating the abovementioned cancer cells. The medicinal compositions include not only the compounds of Antroquinonol B and Antroquinonol C, but also the pharmaceutically accepted carries. The carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners. The inventive composition can be manufactured through mixing the compounds of Antroquinonol B or Antroquinonol C with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated, but are not limited to, as a powder, tablet, capsule, pellets, granules or other liquid formulation.

Claims (16)

1. A compound having the following formula, wherein X is hydroxyl (—OH) or methoxy (—OCH3).
Figure US20080119565A1-20080522-C00004
2. The compound as claimed in claim 1, wherein the compound is isolated from Antrodia camphorata.
3. The compound as claimed in claim 1, wherein the compound is Antroquinonol B when x is hydroxyl (OH).
4. The compound as claimed in claim 3, wherein the compound Antroquinonol B is isolated from Antrodia camphorata.
5. The compound as claimed in claim 1, wherein the compound is Antroquinonol C when x is methoxy (OCH3).
6. The compound as claimed in claim 5, wherein the compound Antroquinonol C is isolated from Antrodia camphorata.
7. A compound as claimed in claim 3 used in inhibiting growth of cancer cells, wherein the cancer cells are breast cancer cells, hepatic cancer cells, or prostate cancer cells.
8. The compound as claimed in claim 7, wherein the breast cancer cells are selected from the group consisting of: breast cancer cell line MCF-7; and breast cancer cell line MDA-MB-231.
9. The compound as claimed in claim 7, wherein the hepatic cancer cells are selected from the group consisting of: hepatic cancer cell line Hep3B; and hepatic cancer cell line HepG2.
10. The compound as claimed in claim 7, wherein the prostate cancer cells are selected from the group consisting of: prostate cancer cell line LNCaP; and prostate cancer cell line DU145.
11. A medicinal composition used in inhibiting growth of tumor cells, which comprises a compound as claimed in claim 3 and a pharmaceutically-acceptable carrier, wherein the tumor cells are selected from the group consisting of: breast cancer, hepatic cancer, and prostate cancer.
12. A compound as claimed in claim 5 used in inhibiting growth of cancer cells, wherein the cancer cells are breast cancer cells, hepatic cancer cells, or prostate cancer cells.
13. The compound as claimed in claim 12, wherein the breast cancer cells are selected from the group consisting of: breast cancer cell line MCF-7; and breast cancer cell line MDA-MB-231.
14. The compound as claimed in claim 12, wherein the hepatic cancer cells are selected from the group consisting of: hepatic cancer cell line Hep3B; and hepatic cancer cell line HepG2.
15. The compound as claimed in claim 12, wherein the prostate cancer cells are selected from the group consisting of: prostate cancer cell line LNCaP; and prostate cancer cell line DU145.
16. A medicinal composition used in inhibiting growth of tumor cells, which comprises a compound as claimed in claim 5 and a pharmaceutically-acceptable carrier, wherein the tumor cells are selected from the group consisting of breast cancer, hepatic cancer, and prostate cancer.
US12/021,584 2007-10-19 2008-01-29 Compounds from Antrodia camphorata Active US7385088B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW096139241 2007-10-19
TW096139241A TW200918498A (en) 2007-10-19 2007-10-19 Novel compound isolated from Antrodia camphorate extracts

Publications (2)

Publication Number Publication Date
US20080119565A1 true US20080119565A1 (en) 2008-05-22
US7385088B1 US7385088B1 (en) 2008-06-10

Family

ID=39417715

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/021,584 Active US7385088B1 (en) 2007-10-19 2008-01-29 Compounds from Antrodia camphorata

Country Status (7)

Country Link
US (1) US7385088B1 (en)
JP (1) JP5014959B2 (en)
KR (1) KR100897988B1 (en)
DE (1) DE102008009039B4 (en)
FR (1) FR2922549B1 (en)
GB (1) GB2453808B (en)
TW (1) TW200918498A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2329816A1 (en) * 2009-11-26 2011-06-08 National Taiwan University An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof
US8648117B2 (en) 2012-02-23 2014-02-11 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
TWI460157B (en) * 2012-07-13 2014-11-11 New Bellus Entpr Co Ltd Compounds from mycelium of antrodia cinnamomea and use thereof
EP2746268A4 (en) * 2011-08-10 2015-09-16 Yang Zhen Method for chemical synthesis of antrocin and use thereof for suppressing non-small cell lung cancer
CN104906147A (en) * 2015-05-12 2015-09-16 柳州市耕青科技有限公司 Method for extracting terpene powder from Antrodia camphorata
WO2016107582A1 (en) 2014-12-30 2016-07-07 Oneness Biotech Co., Ltd. Compounds from antrodia camphorata, method for preparing the same and use thereof
US20170042912A1 (en) * 2015-08-12 2017-02-16 Ma Shen Kai Ruei Co., Ltd. Pharmaceutical composition for treating cancer in an individual subject suffering cancer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101417934B (en) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 New compounds separated from Antrodia camphorate extract
US8309611B2 (en) * 2010-09-20 2012-11-13 Golden Biotechnology Corporation Methods and compositions for treating lung cancer
TWI407100B (en) * 2010-10-21 2013-09-01 Yew Min Tzeng Method for hplc analysis of triterpenoids from antrodia camphorata
TWI452032B (en) 2011-01-21 2014-09-11 Golden Biotechnology Corp Compositions for treating kidney disorders
TWI597061B (en) * 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 Methods and compositions for treating leukemia
JP5908002B2 (en) * 2013-03-20 2016-04-26 卉菱 曽 Compounds contained in Benix nokitake and uses thereof
TW201442700A (en) * 2013-05-09 2014-11-16 Hui-Ling Zeng Antrodia camphorata compound, extract and applications thereof
CN103740772B (en) * 2013-12-27 2015-08-19 江南大学 A kind of method promoting camphor tree sesame liquid state fermentation biosynthesizing Android tonquinol
US9789153B2 (en) 2014-07-02 2017-10-17 Hsiu-Hsien Tsai Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs
CN105769834A (en) * 2014-08-15 2016-07-20 曾泰霖 Application of Antrodia camphorate compound and extract to preparation of drug used for promoting insulin secretion
CN105820956B (en) * 2015-01-04 2019-09-06 上海理工大学 One plant of Antrodia camphorata bacterial strain and Antrodia camphorata liquid state fermentation method
JP6499740B2 (en) * 2016-10-13 2019-04-10 フォーデイズ株式会社 Food composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116787A1 (en) * 2005-11-21 2007-05-24 Chih-Jung Yao Cancer treatment
JP2007267685A (en) * 2006-03-31 2007-10-18 Nissei Bio Kk Method for culturing lactic acid bacterium using filamentous bacterium and cultured product obtained by the same method for culturing

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2329816A1 (en) * 2009-11-26 2011-06-08 National Taiwan University An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof
US20130129773A1 (en) * 2009-11-26 2013-05-23 National Taiwan University Anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof
US9950021B2 (en) * 2009-11-26 2018-04-24 National Taiwan University Anti-cancer active substance from Antrodia camphorata, method for preparing the same and use thereof
EP2746268A4 (en) * 2011-08-10 2015-09-16 Yang Zhen Method for chemical synthesis of antrocin and use thereof for suppressing non-small cell lung cancer
US8648117B2 (en) 2012-02-23 2014-02-11 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
TWI460157B (en) * 2012-07-13 2014-11-11 New Bellus Entpr Co Ltd Compounds from mycelium of antrodia cinnamomea and use thereof
WO2016107582A1 (en) 2014-12-30 2016-07-07 Oneness Biotech Co., Ltd. Compounds from antrodia camphorata, method for preparing the same and use thereof
CN104906147A (en) * 2015-05-12 2015-09-16 柳州市耕青科技有限公司 Method for extracting terpene powder from Antrodia camphorata
US20170042912A1 (en) * 2015-08-12 2017-02-16 Ma Shen Kai Ruei Co., Ltd. Pharmaceutical composition for treating cancer in an individual subject suffering cancer

Also Published As

Publication number Publication date
TW200918498A (en) 2009-05-01
FR2922549B1 (en) 2013-08-23
GB2453808B (en) 2009-09-16
US7385088B1 (en) 2008-06-10
KR100897988B1 (en) 2009-05-18
JP5014959B2 (en) 2012-08-29
GB2453808A8 (en) 2009-05-06
GB0801621D0 (en) 2008-03-05
DE102008009039A1 (en) 2009-04-23
GB2453808A (en) 2009-04-22
FR2922549A1 (en) 2009-04-24
DE102008009039B4 (en) 2009-11-12
TWI335314B (en) 2011-01-01
KR20090040194A (en) 2009-04-23
JP2009102286A (en) 2009-05-14

Similar Documents

Publication Publication Date Title
US7385088B1 (en) Compounds from Antrodia camphorata
US7342137B1 (en) Cyclohexenone compounds from Antrodia camphorata and application thereof
EP2233463A1 (en) New compounds isolated from extract of antrodia camphorata
US7411003B1 (en) Inhibition of Hepatitis B virus by cyclohexenone compounds from Antrodia camphorata
RU2422431C2 (en) New cyclohexenone compounds of antrodia camphorata and their application
US20110060058A1 (en) Inhibition of the Survival of Ovarian Cancer by Cyclohexenone Compounds from Antrodia Camphorata
US8236860B2 (en) Inhibition of the survival of pancreatic cancer by cyclohexenone compounds from Antrodia camphorata
US20130005826A1 (en) Inhibition of the Survival of Gastric Cancer by Cyclohexenone Compounds from Antrodia Camphorata
US20110059123A1 (en) Inhibition of the Survival of Colorectal Cancer by Cyclohexenone Compounds from Antrodia Camphorata
US9622990B2 (en) Method for inhibiting cancer cell growth
US20130005825A1 (en) Inhibition of the Survival of Lymphoma by Cyclohexenone Compounds from Antrodia Camphorata
US20120322890A1 (en) Inhibition of the Survival of Bone Cancer by Cyclohexenone Compounds from Antrodia Camphorata
CN101343247B (en) Cyclohexenone extract of antrodia camphorata
US20130005827A1 (en) Inhibition of the Survival of Bladder Cancer by Cyclohexenone Compounds from Antrodia Camphorata
US20120277320A1 (en) Inhibition of the survival of skin cancer by cyclohexenone compounds from antrodia camphorata
US9474775B2 (en) Compound, extract isolated from antrodia camphorate, and method using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: GOLDEN BIOTECHNOLOGY CORPORATION, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, SHENG-YUN;KUO, MAO-TIEN;WEN, WU-CHE;REEL/FRAME:020432/0736

Effective date: 20080110

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 12